Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

References for PMC Articles for PubMed (Select 22912565)


Discovery and explanation of drug-drug interactions via text mining.

Percha B, Garten Y, Altman RB.

Pac Symp Biocomput. 2012:410-21.


Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.

Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y.

Clin Pharmacol Ther. 2011 Oct;90(4):575-81. doi: 10.1038/clpt.2011.142. Epub 2011 Aug 10.


A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports.

Tatonetti NP, Fernald GH, Altman RB.

J Am Med Inform Assoc. 2012 Jan-Feb;19(1):79-85. doi: 10.1136/amiajnl-2011-000214. Epub 2011 Jun 14.


Using a shallow linguistic kernel for drug-drug interaction extraction.

Segura-Bedmar I, Martínez P, de Pablo-Sánchez C.

J Biomed Inform. 2011 Oct;44(5):789-804. doi: 10.1016/j.jbi.2011.04.005. Epub 2011 Apr 24.


A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents.

Segura-Bedmar I, Martínez P, de Pablo-Sánchez C.

BMC Bioinformatics. 2011 Mar 29;12 Suppl 2:S1. doi: 10.1186/1471-2105-12-S2-S1.


Analysing biological pathways in genome-wide association studies.

Wang K, Li M, Hakonarson H.

Nat Rev Genet. 2010 Dec;11(12):843-54. doi: 10.1038/nrg2884. Review.


DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.

Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.

Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. doi: 10.1093/nar/gkq1126. Epub 2010 Nov 8.


Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.

Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J.

Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010.


Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism.

Tari L, Anwar S, Liang S, Cai J, Baral C.

Bioinformatics. 2010 Sep 15;26(18):i547-53. doi: 10.1093/bioinformatics/btq382.


Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.

Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA.

Pharmacotherapy. 2010 Aug;30(8):787-96. doi: 10.1592/phco.30.8.787.


Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.

Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S.

Clin Pharmacol Ther. 2010 Aug;88(2):214-22. doi: 10.1038/clpt.2010.74. Epub 2010 Jun 30.


Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.

Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Review.


Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD.

Drug Metab Dispos. 2010 Feb;38(2):241-8. doi: 10.1124/dmd.109.028746. Epub 2009 Nov 2.


Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation.

Hurst FP, Neff RT, Jindal RM, Roberts JR, Lentine KL, Agodoa LY, Abbott KC.

Nephrol Dial Transplant. 2009 Dec;24(12):3861-6. doi: 10.1093/ndt/gfp416. Epub 2009 Sep 3.


Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions.

Boyce R, Collins C, Horn J, Kalet I.

J Biomed Inform. 2009 Dec;42(6):990-1003. doi: 10.1016/j.jbi.2009.05.010. Epub 2009 Jun 16.


Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding.

Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S.

Clin Pharmacol Ther. 2008 Nov;84(5):581-8. doi: 10.1038/clpt.2008.150. Epub 2008 Aug 6.


SLCO1B1 variants and statin-induced myopathy--a genomewide study.

SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R.

N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.


New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.

Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ.

J Clin Pharmacol. 2008 Jun;48(6):662-70. doi: 10.1177/0091270007312153. Epub 2008 Mar 31. Review.


Hospitalisations and emergency department visits due to drug-drug interactions: a literature review.

Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH.

Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):641-51. Review.


Risk factors for statin-associated rhabdomyolysis.

Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D.

Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):352-8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk